Journal of Clinical Oncology, Vol 12, 1547-1552, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer

K Kubota, K Furuse, M Kawahara, N Kodama, M Yamamoto, M Ogawara, S Negoro, N Masuda, M Takada and K Matsui
Department of Internal Medicine, National Kinki Central Hospital for Chest Diseases, Sakai, Japan.

PURPOSE: For patients with locally advanced (stage III) non-small-cell lung cancer (NSCLC), radiotherapy (RT) has been used conventionally for many years. Few prospective trials have determined the role of RT. Recently, chemotherapy (CT) has been shown to produce excellent responses in regionally advanced disease. We therefore conducted a randomized trial using cisplatin (P)-based CT regimens with or without thoracic irradiation. PATIENTS AND METHODS: We randomly assigned 92 patients with locally advanced NSCLC to receive one of three arms of P- based combination chemotherapy: vindesine (V) plus P, mitomycin (M) plus V plus P, or etoposide (E) plus P alternating with V plus M. After two cycles of CT, patients were reevaluated and those with stage III were again randomized to receive RT or not. RT consisted of 50 to 60 Gy in 5 to 6 weeks; 2 Gy was delivered once daily in conventional fractions. RESULTS: Sixty-three patients were included in the second randomization. The patients in the CT/RT group (n = 32) and CT-alone group (n = 31) were comparable in terms of age, sex, performance status, histologic features, stage of disease, and induction CT regimen. The median durations of survival were similar for the two groups (461 days in CT/RT group and 447 days in CT-alone group). The survival rate in the CT/RT group was 58% at 1 year, 36% at 2 years, and 29% at 3 years, as compared with 66%, 9%, and 3% at 1, 2, and 3 years, respectively, in the CT-alone group. One patient in the CT/RT group died of pneumonitis, but there were no CT-related deaths. CONCLUSION: In locally advanced NSCLC, P-based combination CT followed by chest irradiation significantly increases the number of long-term survivors as compared with CT alone. RT to bulky disease in the thorax is thus an important part of combined modality therapy, and a necessary part of further studies in locally advanced disease.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Thatcher, C. Faivre-Finn, F. Blackhall, H. Anderson, and P. Lorigan Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5051s - 5056s. [Abstract] [Full Text] [PDF]

				K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, N. Katakami, T. Sugiura, M. Kawahara, A. Yokoyama, S. Yokota, et al. Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group J. Clin. Oncol., January 15, 2004; 22(2): 254 - 261. [Abstract] [Full Text] [PDF]

				J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477. [Abstract] [Full Text] [PDF]

				R. B. Bonnet, D. Bush, G. A. Cheek, J. D. Slater, D. Panossian, C. Franke, and J. M. Slater Effects of Proton and Combined Proton/Photon Beam Radiation on Pulmonary Function in Patients With Resectable but Medically Inoperable Non-small Cell Lung Cancer Chest, December 1, 2001; 120(6): 1803 - 1810. [Abstract] [Full Text] [PDF]

				S. Tsuchiya, Y. Ohe, T. Sugiura, N. Fuwa, Y. Kitamoto, K. Mori, H. Kobayashi, K. Nakata, T. Sawa, K. Hirai, et al. Randomized Phase I Study of Standard-fractionated or Accelerated-hyperfractionated Radiotherapy with Concurrent Cisplatin and Vindesine for Unresectable Non-Small Cell Lung Cancer: a Report of Japan Clinical Oncology Group Study (JCOG 9601) Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 488 - 494. [Abstract] [Full Text] [PDF]

				K. Furuse, M. Fukuoka, M. Kawahara, H. Nishikawa, Y. Takada, S. Kudoh, N. Katagami, and Y. Ariyoshi Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2692 - 2692. [Abstract] [Full Text] [PDF]

				M. J. Edelman, D. R. Gandara, M. Roach III, and J. R. Benfield Multimodality Therapy in Stage III Non-Small Cell Lung Cancer Ann. Thorac. Surg., May 1, 1996; 61(5): 1564 - 1572. [Abstract] [Full Text]